TG Therapeutics (TGTX) Presents at Rodman & Renshaw Conference

TG Therapeutics, Inc. (NASDAQ:TGTX) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies: TG-1101 and TGR-1202, both of which are in clinical development for patients with hematologic malignancies. The company also has pre-clinical programs to develop IRAK4 inhibitors, and anti-PD-L1 and anti-GITR antibodies. For more information, visit the company’s website at www.tgtherapeutics.com